Verona Pharma Files 8-K on Officer/Director Changes
| Field | Detail |
|---|---|
| Company | Verona Pharma PLC |
| Form Type | 8-K |
| Filed Date | Sep 9, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, corporate-governance, filing
TL;DR
Verona Pharma's 8-K signals leadership changes and executive compensation updates.
AI Summary
Verona Pharma plc filed an 8-K on September 9, 2025, reporting events as of September 5, 2025. The filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes financial statements and exhibits.
Why It Matters
This filing indicates potential shifts in the leadership and governance structure of Verona Pharma, which could impact strategic direction and operational oversight.
Risk Assessment
Risk Level: medium — Changes in key personnel and executive compensation can signal internal shifts that may affect company strategy or performance.
Key Players & Entities
- Verona Pharma plc (company) — Registrant
- September 5, 2025 (date) — Date of earliest event reported
- September 9, 2025 (date) — Date of Report
FAQ
What specific roles have seen departures or appointments?
The filing indicates changes related to the departure of directors or certain officers, election of directors, and appointment of certain officers, but does not specify the exact roles in the provided text.
Are there any details on the compensatory arrangements mentioned?
The filing states that compensatory arrangements of certain officers are part of the reported items, but specific details are not included in the provided text.
What is the primary business of Verona Pharma plc?
Verona Pharma plc is in the business of Pharmaceutical Preparations, as indicated by its Standard Industrial Classification code [2834].
Where is Verona Pharma plc's principal executive office located?
Verona Pharma plc's principal executive offices are located at 3 More London Riverside, London, SE1 2RE, United Kingdom.
What is the SEC file number for Verona Pharma plc?
The SEC file number for Verona Pharma plc is 001-38067.
Filing Stats: 717 words · 3 min read · ~2 pages · Grade level 13.7 · Accepted 2025-09-09 16:05:33
Filing Documents
- tm2525478d1_8k.htm (8-K) — 27KB
- tm2525478d1_ex10-1.htm (EX-10.1) — 12KB
- 0001104659-25-088613.txt ( ) — 204KB
- vrna-20250905.xsd (EX-101.SCH) — 3KB
- vrna-20250905_lab.xml (EX-101.LAB) — 33KB
- vrna-20250905_pre.xml (EX-101.PRE) — 22KB
- tm2525478d1_8k_htm.xml (XML) — 4KB
02. Departure of Directors or Certain Officers; Election
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 5, 2025, the Remuneration Committee of the Board of Directors of Verona Pharma plc (the "Company") approved an amendment (the "Amendment") to the Verona Pharma plc Employee Change in Control Severance Benefit Plan (as amended and/or restated from time to time, the "Severance Plan"), subject to the occurrence of the Closing (as defined in the Transaction Agreement, dated as of July 8, 2025, by and among Merck Sharp & Dohme LLC, Vol Holdings LLC and the Company (the "Transaction Agreement")) and effective as of immediately prior to the Closing. Pursuant to the Amendment, (i) the time period following a Change in Control (as defined in the Severance Plan) in which a qualifying termination of employment may occur resulting in severance benefits under the Severance Plan shall be extended from twelve months to twenty-four months; (ii) the definition of a "Qualifying Resignation" shall be revised to generally mean an eligible employee's resignation after receiving and declining a long-term offer of employment from the Company after completing any reasonable knowledge transfer and administrative support requests; and (iii) the minimum severance period for benefits available under the Severance Plan shall be increased from three months to six months . I n the event that the Transaction Agreement is terminated prior to the occurrence of the Closing, the Amendment shall be void. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Amendment to Verona Pharma plc Employee Change in Control Severance Benefit Plan. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VERONA PHARMA PLC Date: September 9, 2025 By: /s/ David Zaccardelli, Pharm. D. Name: David Zaccardelli, Pharm. D. Title: President and Chief Executive Officer